Lamas et al report results of the Trial to Assess Chelation Therapy (TACT), a randomized controlled trial analyzing whether EDTA-based chelation therapy reduced cardiovascular events in 1708 patients with a history of myocardial infarction. In editorials, Nissen and Bauchner et al discuss the evaluation of TACT.
To determine the efficacy of macrolide maintenance treatment for adults with non–cystic fibrosis bronchiectasis, Altenburg and coauthors randomized 83 outpatients with 3 or more lower respiratory tract infections in the preceding year to receive azithromycin or placebo for 12 months. Elborn and Tunney provide comment in the related Editorial.
Serisier and coauthors evaluate the clinical efficacy and antimicrobial resistance cost of low-dose erythromycin for patients with non–cystic fibrosis bronchiectasis in a 12-month, double-blind, placebo-controlled trial. In an Editorial, Elborn and Tunney discuss long-term macrolide therapy for patients with bronchiectasis.
To determine the effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction, Redfield and coauthors conducted a trial of 216 patients randomized to sildenafil or placebo and measured peak oxygen consumption along with a variety of clinical status variables.
Lin and coauthors report on the use of sublingual immunotherapy as a treatment for allergic rhinoconjunctivitis and asthma. In an accompanying Editorial, Nelson discusses whether sublingual immuotherapy is ready for use in the United States.